[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Soussain C, Hoang-Xuan K, Levy V: [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]. Bull Cancer; 2004 Feb;91(2):189-92
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
  • [Transliterated title] Chimiothérapie intensive avec support hématopoïétique chez 22 patients ayant un lymphome primitif du système nerveux central ou un lymphome intraoculaire réfractaire ou en rechute: mise à jour des résultats.
  • Rescue therapies for relapsing/refractory primary central nervous system lymphoma (PCNSL) and intraocular lymphoma (IOL) remain a challenging problem for clinicians.
  • In 2001, we published encouraging results for 22 patients treated at relapse with a CYVE regimen combining high doses of Ara-C (50 mg/m(2)/d in 12 hours infusion dl through d5; 2 g/m(2)/d d2 through d5) and VP16 (200 mg/m(2)/d d2 through d5), followed by intensive chemotherapy based on high doses of thiotepa (250 mg/m(2)/d d-9 through d-7), busulfan (10 mg/kg total dose d-6 through d-4) and cyclophosphamide (60 mg/kg/d, d-3 and d-2 with hematopoietic cell rescue at d0.
  • CYVE rescue was not administered to patients with refractory IOL who had previously received high doses of methotrexate and Ara-C as part of their first-line treatment.
  • Twenty patients received the intensive chemotherapy and hematopoietic cells rescue.
  • Seven patients had neurologic adverse events during the entire procedure.
  • With a median follow up of 6.2 years, the median overall survival is 91 months, and the median survival after intensive chemotherapy has not been reached.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Busulfan / adverse effects. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Etoposide / administration & dosage. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / therapy. Middle Aged. Prognosis. Recurrence. Thiotepa / administration & dosage. Thiotepa / adverse effects

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright John Libbey Eurotext 2003.
  • (PMID = 15047459.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


2. Faia LJ, Chan CC: Primary intraocular lymphoma. Arch Pathol Lab Med; 2009 Aug;133(8):1228-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intraocular lymphoma.
  • Primary intraocular lymphoma, recently suggested to be renamed primary retinal lymphoma, is a subset of primary central nervous system lymphoma and is usually an aggressive diffuse large B-cell lymphoma.
  • Between 56% and 85% of patients who initially present with primary intraocular lymphoma alone will develop cerebral lesions.
  • The diagnosis of primary intraocular lymphoma can be difficult to make and requires tissue for diagnosis.
  • The atypical lymphoid cells are large and display a high nuclear to cytoplasmic ratio, prominent nucleoli, and basophilic cytoplasm.
  • Flow cytometry, immunohistochemistry, cytokine analysis, and gene rearrangements also aid in the diagnosis.
  • Local and systemic treatments, such as chemotherapy and radiation, are employed, although the relapse rate remains high.
  • [MeSH-major] Eye Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA, Neoplasm / analysis. Diagnosis, Differential. Flow Cytometry. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Uveitis / diagnosis

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):742-9 [11157026.001]
  • [Cites] Ophthalmology. 2008 Nov;115(11):1944-50 [18672292.001]
  • [Cites] Retina. 2002 Feb;22(1):37-43 [11884876.001]
  • [Cites] Surv Ophthalmol. 2002 Mar-Apr;47(2):81-124 [11918892.001]
  • [Cites] Arch Ophthalmol. 2002 Nov;120(11):1534-9 [12427068.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Ophthalmology. 2003 Feb;110(2):421-6 [12578791.001]
  • [Cites] Eye (Lond). 2003 May;17(4):513-21 [12802353.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1671-2 [12917196.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Clin Infect Dis. 2004 Jul 15;39(2):173-8 [15307025.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):285-95 [15377987.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1399-406 [8371930.001]
  • [Cites] Leuk Lymphoma. 1994 Jan;12(3-4):205-10 [8167552.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Ophthalmology. 1998 Sep;105(9):1664-9 [9754175.001]
  • [Cites] Arch Ophthalmol. 1999 Jun;117(6):761-5 [10369586.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1805-10 [10485554.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Am J Ophthalmol. 2005 Mar;139(3):573-4 [15767087.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Nov;46(11):3957-64 [16249468.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10586-93 [17079483.001]
  • [Cites] Int Ophthalmol. 2007 Aug;27(4):241-50 [17440686.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3253-9 [17591896.001]
  • [Cites] Ann Oncol. 2007 Nov;18(11):1851-5 [17804469.001]
  • [Cites] Surv Ophthalmol. 2007 Nov-Dec;52(6):561-87 [18029267.001]
  • [Cites] Arch Ophthalmol. 2008 Jul;126(7):1002-3 [18625954.001]
  • [Cites] Jpn J Ophthalmol. 2008 May-Jun;52(3):167-74 [18661266.001]
  • [Cites] Clin Experiment Ophthalmol. 2008 Aug;36(6):564-78 [18954321.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • (PMID = 19653715.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains
  • [Other-IDs] NLM/ NIHMS138864; NLM/ PMC2732907
  •  go-up   go-down


3. Auw-Haedrich C, Coupland SE, Kapp A, Schmitt-Gräff A, Buchen R, Witschel H: Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma. Br J Ophthalmol; 2001 Jan;85(1):63-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma.
  • AIM: To classify ocular adnexal lymphomas according to the Revised European and American Lymphoma (REAL) classification and to determine any correlation between clinical features or histomorphological variables with the patients' outcome.
  • METHODS: Conventional and immunohistology were performed on representative sections of 53 specimens of 46 patients with ocular adnexal lymphoma.
  • The Student's t test and log rank test were used for statistical analysis.
  • Almost all specimens represented B cell non-Hodgkin's lymphomas: extranodal marginal zone lymphoma (EMZL) (n=38), diffuse large cell B cell lymphoma (n=8), lymphoplasmocytic lymphoma/immunocytoma (n=2), mantle cell lymphoma (n=2), follicle centre lymphoma (n=1), and plasmacytoma (n=1).
  • One case of a secondary anaplastic large cell lymphoma of T cell type (T-ALCL) was diagnosed.
  • A variety of therapeutic regimens was administered, the main form of treatment being radiotherapy.
  • The average follow up time was 85 months.
  • Complete remission was achieved in 24 patients (10 after excision alone, eight after radiotherapy alone, three after combined excision and radiotherapy, one after chemotherapy alone, and two after combined radiotherapy and chemotherapy).
  • 12 patients died of causes related to lymphoma; in one patient the cause of death was unknown.
  • The stage at presentation, as well as the lymphoma malignancy category, had a significant correlation with the final course of the disease (p=0.0001 and p=0.03, respectively).
  • A significant correlation was also noted between the final outcome (p<0.05) and tumour cell expression for Ki-67 antigen and p53 protein.
  • CONCLUSION: 67% of patients with ocular adnexal lymphoma had EMZL.
  • Primary diffuse large cell B cell lymphoma of the ocular adnexa requires at least similar therapeutic measures and regular intensive follow up.
  • [MeSH-major] Eye Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1996 Jan;105(1):31-7 [8561085.001]
  • [Cites] J Pathol. 1994 Aug;173(4):371-9 [7965396.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):779-81 [9739446.001]
  • [Cites] Br J Ophthalmol. 1999 Jun;83(6):742-7 [10340987.001]
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1869-70 [5121698.001]
  • [Cites] Ophthalmology. 1979 May;86(5):948-66 [545222.001]
  • [Cites] Cancer. 1980 Aug 1;46(3):576-89 [6994870.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Ann Ophthalmol. 1984 Nov;16(11):1046-55 [6549113.001]
  • [Cites] Ophthalmology. 1985 Oct;92(10):1311-24 [3906488.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2121-9 [2804350.001]
  • [Cites] Trans Am Ophthalmol Soc. 1989;87:420-42; discussion 442-4 [2562543.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):959-73 [2394438.001]
  • [Cites] Pathol Res Pract. 1991 Jan;187(1):78-84 [2027825.001]
  • [Cites] Mayo Clin Proc. 1993 Oct;68(10):1003-10 [8412350.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1994-2006 [9098307.001]
  • (PMID = 11133714.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1723704
  •  go-up   go-down


Advertisement
4. Jahnke K, Thiel E, Abrey LE, Neuwelt EA, Korfel A: Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol; 2007 Sep;1(3):247-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of primary intraocular lymphoma: an update.
  • Despite recent advances in diagnosis and treatment, the prognosis of primary intraocular lymphoma (PIOL) remains poor, and the optimal treatment has yet to be defined.
  • This review presents an overview of the current status of PIOL with a focus on recent advances in diagnosis and treatment.
  • Recent studies show a decreasing time interval from symptom presentation to diagnosis, likely due to increased awareness of the disease and improved diagnostic tools.
  • Advances in the pathologic characterization of PIOL have been made over the past years, and the development of PIOL animal models can offer the opportunity to study aspects of PIOL pathology, pathogenesis and treatment.
  • Regarding treatment of PIOL, recent larger case series favor the use of systemic chemotherapy plus local ocular treatment as first-line management for patients with concomitant PIOL and PCNSL.
  • For patients with isolated PIOL, the current trend focuses on local first-line treatment and early diagnosis of PIOL.
  • Future directions in the management of PIOL should include studies about pathogenesis, prognostic factors, and treatment optimization.
  • In the future, monoclonal antibodies and radioimmunotherapy could prove useful for PIOL treatment.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2000 Jan;46(1):51-60; discussion 60-1 [10626935.001]
  • [Cites] Surv Ophthalmol. 2000 May-Jun;44(6):518-26 [10906383.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1359-70 [11002232.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):742-9 [11157026.001]
  • [Cites] Ophthalmology. 2001 Feb;108(2):386-99 [11158819.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):426-7 [11237883.001]
  • [Cites] Oncology. 2001;60(2):134-40 [11244328.001]
  • [Cites] Ocul Immunol Inflamm. 2000 Dec;8(4):243-50 [11262654.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):137-42 [11307054.001]
  • [Cites] Neurosurgery. 2001 May;48(5):1033-40; discussion 1040-1 [11334269.001]
  • [Cites] Retina. 2001;21(3):281-4 [11421029.001]
  • [Cites] Exp Eye Res. 2001 Nov;73(5):581-92 [11747359.001]
  • [Cites] Ophthalmology. 2002 Feb;109(2):235-42 [11825801.001]
  • [Cites] Ann Neurol. 2002 Feb;51(2):247-52 [11835382.001]
  • [Cites] Retina. 2002 Feb;22(1):37-43 [11884876.001]
  • [Cites] Curr Mol Med. 2001 May;1(2):259-72 [11899075.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):531-8 [12056702.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):193-202 [12115333.001]
  • [Cites] J Neurol. 2002 Dec;249(12):1713-6 [12529795.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):711-5 [12576439.001]
  • [Cites] Ophthalmology. 2003 Feb;110(2):421-6 [12578791.001]
  • [Cites] Ophthalmology. 2003 Mar;110(3):595-9 [12623828.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):739-49, viii [16083834.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1974-8 [16219622.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):139-45 [15221999.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Sep;242(9):771-6 [15349786.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):901-3 [15365145.001]
  • [Cites] Br J Ophthalmol. 2005 Feb;89(2):238-9 [15665359.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):189-97 [15806372.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):591-7 [15973665.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3507-14 [16186327.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Nov;46(11):3957-64 [16249468.001]
  • [Cites] Br J Ophthalmol. 2006 Jun;90(6):690-2 [16488933.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3865-70 [16864853.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4754-7 [16966685.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10586-93 [17079483.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2750-6 [16799010.001]
  • [Cites] Semin Ophthalmol. 2006 Jul-Sep;21(3):125-33 [16912010.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1800-5 [17064991.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E3 [17134119.001]
  • [Cites] Surv Ophthalmol. 1979 Mar-Apr;23(5):279-96 [380030.001]
  • [Cites] Exp Eye Res. 1977;25 Suppl:27-63 [412691.001]
  • [Cites] Surv Ophthalmol. 1975 Jan-Feb;19(4):224-39 [1089323.001]
  • [Cites] Ophthalmology. 1992 Feb;99(2):250-6 [1553217.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):339-45 [9031115.001]
  • [Cites] Retina. 1997;17(2):118-23 [9143039.001]
  • [Cites] J Neurooncol. 2002 Jun;58(2):175-8 [12164690.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1709-16 [12208721.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2006 Jun;244(6):663-9 [16228920.001]
  • [Cites] Exp Eye Res. 2006 May;82(5):760-6 [16289160.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Mar;4(3):225-31 [16728934.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1152-6 [9298056.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1157-60 [9298057.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):362-72 [9439362.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3000-6 [9738568.001]
  • [Cites] Ophthalmology. 1998 Sep;105(9):1664-9 [9754175.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):559-63 [10078637.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2749-51 [10232895.001]
  • [Cites] Br J Ophthalmol. 1999 Apr;83(4):448-51 [10434868.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1329 [10561199.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Ophthalmology. 1999 Dec;106(12):2291-5 [10599659.001]
  • [Cites] Ophthalmology. 2003 Jun;110(6):1241-4 [12799254.001]
  • [Cites] Eye (Lond). 2003 May;17(4):513-21 [12802353.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2407-14 [12805341.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1671-2 [12917196.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2003 Oct;241(10):860-70 [14605902.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4151-6 [14615443.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5235-41 [14638722.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Ocul Immunol Inflamm. 2004 Mar;12(1):7-16 [15209459.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1762-7 [15350334.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):285-95 [15377987.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):901-13 [15565454.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Feb;46(2):415-9 [15671263.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Ann Neurol. 2005 Jun;57(6):843-7 [15929034.001]
  • [Cites] Blood. 2005 Jul 1;106(1):384-5 [15967804.001]
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1273-5 [2418934.001]
  • [Cites] Cancer. 1989 May 15;63(10):1918-21 [2702565.001]
  • [Cites] Ophthalmology. 1988 May;95(5):625-30 [3050698.001]
  • [Cites] Br J Ophthalmol. 1988 Dec;72(12):905-11 [3067746.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):835-53 [3286832.001]
  • [Cites] Br J Ophthalmol. 1987 Oct;71(10):748-52 [3314978.001]
  • [Cites] Ophthalmology. 1987 Dec;94(12):1631-9 [3323986.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):688-92 [6766795.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Retina. 1995;15(2):125-9 [7624599.001]
  • [Cites] Ann Intern Med. 1993 Dec 1;119(11):1093-104 [8239229.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1399-406 [8371930.001]
  • [Cites] J Neurooncol. 1995;25(1):67-71 [8523091.001]
  • [Cites] Am J Ophthalmol. 1996 Apr;121(4):442-4 [8604740.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):827-33 [8608471.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):556-64 [8636771.001]
  • [Cites] Retina. 1996;16(1):47-56 [8927810.001]
  • (PMID = 19668478.001).
  • [ISSN] 1177-5467
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2701132
  • [Keywords] NOTNLM ; chemotherapy / diffuse large B-cell lymphoma / non-Hodgkin’s lymphoma / primary central nervous system lymphoma / primary intraocular lymphoma / radiotherapy
  •  go-up   go-down


5. Buc D, Travade P, Kemeny JL, Bacin F: [A case of primary non-Hodgkin lymphoma of the lacrimal sac]. J Fr Ophtalmol; 2002 Nov;25(9):931-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary non-Hodgkin lymphoma of the lacrimal sac].
  • Pathological studies of the mass revealed diffuse malignant lymphoma with large B cells.
  • The lymphoma was classified as stage IIE using Ann Arbor staging after clinical, biological and radiological examination.
  • Six CHOP systemic chemotherapy were proposed.
  • Primary non-Hodgkin lymphoma of the lacrimal sac is extremely rare.
  • Collaboration between the ophthalmologist, anatomopathologist and oncologist allowed us to determine the type and the extension and to propose an aggressive but successful treatment in this highly malignant and very localized lymphoma.
  • [MeSH-major] Eye Neoplasms. Lymphoma, B-Cell. Nasolacrimal Duct
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Dacryocystorhinostomy. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Prednisone / therapeutic use. Time Factors. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12515939.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Planer D, Cukierman T, Liebster D, Ilsar M, Chajek-Shaul T: Anterior uveitis as a complication of treatment with high dose cytosine-arabinoside. Am J Hematol; 2004 Jul;76(3):304-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anterior uveitis as a complication of treatment with high dose cytosine-arabinoside.
  • We present a case of a 21-year-old woman suffering from diffuse large B-cell lymphoma who developed acute anterior uveitis shortly after completing chemotherapeutic course with HYPER-CVAD protocol (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) alternating with methotrexate and high-dose cytosine-arabinoside (HIDAC), with poor adherence to recommended prophylactic treatment with saline eye drops.
  • Complete resolution of her symptoms was achieved within a few days of treatment with topical steroids.
  • To our knowledge this is the first report of acute anterior uveitis secondary to treatment with HIDAC.
  • Differential diagnosis and a suggested mechanism are discussed.
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Uveitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15224375.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine
  •  go-up   go-down


7. Madge SN, McCormick A, Patel I, Hatef E, Menon V, Prabhakaran VC, Irion L, Bonshek R, Honovar S, Leatherbarrow B, Esmaeli B, Selva D: Ocular adnexal diffuse large B-cell lymphoma: local disease correlates with better outcomes. Eye (Lond); 2010 Jun;24(6):954-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular adnexal diffuse large B-cell lymphoma: local disease correlates with better outcomes.
  • PURPOSE: To describe the clinical, immunohistochemical and prognostic features, as well as outcomes of a large series of patients with orbital and periorbital diffuse large B-cell lymphoma (DLBCL).
  • The main outcome measures were patient demographics, clinical features, imaging, immunohistochemical and histopathological data, treatments administered, and survival.
  • RESULTS: A total of 20 out of 37 cases (54.1%) represented localised periorbital disease (group L), 11 of 37 (29.7%) had systemic disease at presentation with periorbital disease (group S1), and 6 of 37 (16.2%) had previous history of systemic lymphoma (group S2).
  • A total of 25 out of 32 patients (78.1%) received chemotherapy, 14 (43.8%) received rituxmab plus chemotherapy, and 19 (59.3%) received radiotherapy.
  • Nine deaths occurred, one in group L (not lymphoma related), six in group S1, and two in group S2.
  • Rituximab plus chemotherapy may be associated with increased survival.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Immunologic Factors. Male. Middle Aged. Prognosis. Retrospective Studies. Rituximab

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942938.001).
  • [ISSN] 1476-5454
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


8. Dorrepaal SJ, Margolin EA, Wang C: Bilateral pseudohypopyon as a presenting feature of recurrent diffuse large B-cell lymphoma. J Neuroophthalmol; 2010 Mar;30(1):67-9
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral pseudohypopyon as a presenting feature of recurrent diffuse large B-cell lymphoma.
  • A 55-year-old man with Gaucher disease and B-cell lymphoma developed a white meniscus along the inferior portion of the anterior chamber of both eyes.
  • In one eye, the meniscus was also temporal, reflecting the fact that he had just been lying on his left side.
  • Aspiration of aqueous fluid confirmed that the meniscus was made up of lymphoma cells, indicating that it was a pseudohypopyon. (A true hypopyon is made up of reactive white blood cells.
  • ) Despite intensive chemotherapy, the patient expired within 14 weeks of the discovery of the pseudohypopyon.
  • This is the first report of binocular pseudohypopyon confirmed as lymphomatous by flow cytometric immunophenotyping analysis in a patient with diffuse large B-cell lymphoma.
  • [MeSH-major] Anterior Chamber / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182212.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Morley AM, Verity DH, Meligonis G, Rose GE: Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit. Orbit; 2009;28(6):425-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
  • OBJECTIVES: To describe two cases of orbital plasmablastic lymphoma (PBL), a recently defined aggressive large-cell lymphoma with a plasmacytic immunophenotype, typically occurring in the oral cavity of HIV+ patients.
  • To compare their presentation, management, immunohistochemistry and prognosis with orbital diffuse large B-cell lymphoma (DLBCL).
  • Both tumours were negative for B-cell markers (CD20, CD79a), showed a plasmacytic immunophenotype (positive for CD 138, Vs38c), and displayed a Ki67 index of 100%.
  • Despite chemotherapy, both patients died within 1 year.
  • Only 7 (50%) had sinus involvement and 3 (21%) had prior systemic lymphoma.
  • All were positive for B-cell markers, with a Ki67 index of 55%-80%.
  • None died within 1 year of diagnosis.
  • It must be considered in the differential of orbital large-cell lymphoid tumours showing plasmablastic morphology or immunophenotype.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Orbital Neoplasms / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Biomarkers, Tumor / analysis. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Fatal Outcome. HIV Infections / complications. HIV Infections / drug therapy. Humans. Immunophenotyping. Male. Middle Aged. Prednisone / therapeutic use. Tomography, X-Ray Computed. Vincristine / therapeutic use


10. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol; 2001 Feb 01;19(3):742-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
  • PURPOSE: To assess the feasibility and efficacy of intensive chemotherapy with hematopoietic stem-cell rescue (IC + HCR) in patients with refractory or recurrent primary CNS lymphoma (PCNSL) or intraocular lymphoma (IOL).
  • Intravenous clonazepam 2 mg/d was given prophylactically from the day before initiation of busulfan therapy to the day after completion of busulfan therapy.
  • Patients with refractory or recurrent PCNSL underwent IC + HCR only if they were chemosensitive to two cycles of salvage treatment with cytarabine (2 g/m(2)/d days 2 through 5 and 50 mg/m(2)/d days 1 through 5 in a 12-hour infusion) and etoposide (VP-16; 200 mg/m(2)/d days 2 through 5) (CYVE).
  • Twenty patients entered the IC + HCR program: twelve entered after CYVE treatment, seven entered directly, and one had previously been retreated with high-dose MTX.
  • Fourteen patients remained alive (median follow-up time, 41.5 months).
  • Seven patients had neurologic adverse events during the entire procedure.
  • The entire procedure seemed to be most toxic in patients > or = 60 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Central Nervous System Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Busulfan / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Feasibility Studies. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / therapy. Male. Methotrexate / administration & dosage. Middle Aged. Nervous System Diseases / chemically induced. Salvage Therapy. Thiotepa / administration & dosage

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11157026.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Fulco PP, Hynicka L, Rackley D: Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother; 2010 Feb;44(2):377-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.
  • OBJECTIVE: To describe the antiretroviral management of a patient diagnosed simultaneously with HIV/AIDS and diffuse large B-cell lymphoma, focusing on the drug-drug interactions between highly active antiretroviral therapy (HAART) and concomitant cancer chemotherapy.
  • CASE SUMMARY: A 55-year-old white man was recently diagnosed with HIV/AIDS and presented 1 month later with complaints of nausea, vomiting, abdominal pain, double vision, right eye discomfort/swelling, and a 3.6-kg weight loss.
  • An excisional biopsy of a right inguinal lymph node confirmed a new diagnosis of diffuse large B-cell lymphoma.
  • As the potential for multiple drug-drug interactions existed, raltegravir, abacavir, and lamivudine were chosen for the initial HAART regimen.
  • DISCUSSION: HAART improves the chemotherapeutic response in patients with HIV and lymphoma.
  • Multiple drug-drug interactions are possible in patients who are to receive CHOP and HAART.
  • Raltegravir, an integrase inhibitor, is eliminated via glucuronidation and results in minimal drug-drug interactions.
  • CONCLUSIONS: There is limited information published regarding the potential for interactions between HAART and cancer chemotherapy.
  • While further research is necessary, it is important for clinicians to consider the potential for drug-drug interactions when designing a HAART regimen concurrently with chemotherapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pyrrolidinones / therapeutic use
  • [MeSH-minor] Antiretroviral Therapy, Highly Active / methods. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Drug Interactions. HIV Integrase Inhibitors / therapeutic use. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / etiology. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / therapeutic use. Raltegravir Potassium. Vincristine / therapeutic use


12. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V, Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol; 2008 May 20;26(15):2512-8
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
  • PURPOSE: The prognosis of relapsing primary CNS lymphoma (PCNSL) is poor.
  • We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment.
  • PATIENTS AND METHODS: Salvage treatment consisted of two cycles of high-dose cytarabine and etoposide (CYVE).
  • Intensive chemotherapy combined thiotepa, busulfan, and cyclophosphamide.
  • Forty-three patients (median age, 52 years; range, 23 to 65 years) were included, with relapse (n = 22), refractory disease (n = 17), or a partial response to first-line treatment (n = 4).
  • The response to CYVE was not assessable in three cases because of treatment-related death.
  • The respective median progression-free survival (PFS) times after IC + HCR were 11.6 and 41.1 months.
  • CONCLUSION: IC + HCR is an effective treatment for refractory and recurrent PCNSL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Thiotepa / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413641.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


13. Park J, Franco RS, Augsburger JJ, Banerjee RK: Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma. Curr Eye Res; 2007 Jul-Aug;32(7-8):659-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma.
  • PURPOSE: Methotrexate (MTX) is the most commonly used chemotherapeutic agent to treat primary central nervous system lymphoma (PCNSL) and intraocular lymphoma (IOL).
  • 2-methoxyestradiol (2ME2) is a potent antitumor and anti-angiogenesis agent which, unlike other cytotoxic drugs, has minimal toxicity.
  • In this study, anti-proliferative, apoptotic, and cell-cycle effects of 2ME2 and MTX were compared to evaluate 2ME2 efficacy in human lymphoma cells, models for non-Hodgkin B cell lymphomas.
  • To detect apoptotic and cell cycle distribution changes induced by 2ME2 and MTX, the cells were stained with Annexin V-FITC and/or propidium iodide (PI) and analyzed by flow cytometry.
  • RESULTS: Lymphoma cell proliferation was inhibited by 50% at concentrations ranging from 0.4 to 1 microM for 2ME2 and 0.06 to 0.2 microM for MTX.
  • 2ME2 was a G2/M-phase specific blocker whereas MTX was an S-phase specific blocker in cell cycle analyses.
  • At 1 microM concentration, 2ME2 and MTX showed similar anti-proliferative effect on the lymphoma cell lines.
  • 2ME2 at a therapeutic target concentration of 1 mu M may be an effective and relatively non-toxic drug for the treatment of PCNSL with IOL.
  • CONCLUSIONS: Our study of the effect of 2ME2 and MTX on anti-proliferation, apoptosis, and cell cycling suggests that 2ME2 is a potential agent for treating PCNSL and IOL.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Estradiol / analogs & derivatives. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Annexin A5 / metabolism. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. Fluorescein-5-isothiocyanate / metabolism. Humans. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852190.001).
  • [ISSN] 0271-3683
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antimetabolites, Antineoplastic; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol; I223NX31W9 / Fluorescein-5-isothiocyanate; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Coupland SE, Heimann H: [Primary intraocular lymphoma]. Ophthalmologe; 2004 Jan;101(1):87-98
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intraocular lymphoma].
  • Primary intraocular lymphoma (PIOL) is a rare extranodal Non-Hodgkin lymphoma (NHL), involving the retina, the subretinal space, vitreous body and/or optic nerve.
  • The majority of PIOL are diffuse large cell B-cell lymphomas according to the new W.H.O. lymphoma classification with an immunophenotype suggesting an origin from germinal centre cells.
  • PIOL occurs independently or together with primary central nervous system lymphoma (PCNSL), and often presents in the form of a steroid-resistant uveitis.
  • Various techniques, particularly the polymerase chain reaction analysing clonal rearrangements of the immunoglobin heavy chain or the T-cell receptor genes, prove to be useful adjuncts.
  • Furthermore, they allow exact subtyping of the malignant lymphoma when present, enabling exclusion of an ocular manifestation of a systemic lymphoma.
  • Currently, most PIOL/PCNSL are treated with systemic chemotherapy.
  • Although the prognosis of patients with PCNS/PIOL remains poor, newer methods enabling earlier diagnosis establishment and treatment are gradually increasing overall survival.
  • [MeSH-major] Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Lymphoma / pathology. Lymphoma / therapy. Methotrexate / therapeutic use. Radiotherapy / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Humans. Practice Patterns, Physicians'

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] Surv Ophthalmol. 2001 May-Jun;45(6):463-71 [11425352.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):843-9 [8334638.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1805-10 [10485554.001]
  • [Cites] Pathologe. 2002 Jul;23(4):284-91 [12185781.001]
  • [Cites] Ophthalmology. 1988 May;95(5):625-30 [3050698.001]
  • [Cites] Am J Ophthalmol. 1997 Mar;123(3):420-2 [9063264.001]
  • [Cites] Arch Ophthalmol. 1989 Mar;107(3):395-7 [2647068.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):339-45 [9031115.001]
  • [Cites] Ocul Immunol Inflamm. 2000 Dec;8(4):243-50 [11262654.001]
  • [Cites] J Pathol. 2002 Jul;197(3):333-40 [12115879.001]
  • [Cites] Ophthalmology. 1993 Dec;100(12):1794-9 [8259276.001]
  • [Cites] Br J Ophthalmol. 1997 Jan;81(1):31-6 [9135405.001]
  • [Cites] Am J Ophthalmol. 1975 Jan;79(1):39-47 [1089097.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Am J Ophthalmol. 1951 Aug;34(8):1153-8 [14857107.001]
  • [Cites] Recent Results Cancer Res. 1994;135:155-69 [8047690.001]
  • [Cites] Arch Ophthalmol. 1999 Jun;117(6):761-5 [10369586.001]
  • [Cites] Bull Soc Belge Ophtalmol. 1994;252:67-73 [7894759.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1997 Jul;235(7):431-6 [9248839.001]
  • [Cites] Trans Am Ophthalmol Soc. 1995;93:281-308; discussion 308-14 [8719683.001]
  • [Cites] Ophthalmology. 1998 Sep;105(9):1664-9 [9754175.001]
  • [Cites] Ophthalmology. 2001 Feb;108(2):386-99 [11158819.001]
  • [Cites] Ophthalmology. 2001 Jul;108(7):1289-95 [11425689.001]
  • [Cites] Ophthalmology. 1993 May;100(5):705-14 [8493014.001]
  • [Cites] Ophthalmology. 1987 Apr;94(4):397-406 [3295641.001]
  • [Cites] Ophthalmology. 1987 Dec;94(12):1631-9 [3323986.001]
  • [Cites] Neurology. 1996 Feb;46(2):435-9 [8614508.001]
  • [Cites] Arch Ophthalmol. 1980 Apr;98(4):707-10 [6989349.001]
  • [Cites] Ophthalmologe. 2001 May;98(5):495-505 [11402836.001]
  • [Cites] Arch Ophthalmol. 1995 Oct;113(10):1233-4 [7575251.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(5):315-6 [8305342.001]
  • [Cites] Retina. 1997;17 (2):118-23 [9143039.001]
  • [Cites] Retina. 1995;15(2):125-9 [7624599.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):688-92 [6766795.001]
  • [Cites] Retina. 1996;16(1):47-56 [8927810.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):362-72 [9439362.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):219-26 [10563426.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Ophthalmology. 1993 Sep;100(9):1399-406 [8371930.001]
  • [Cites] Neurol Clin. 1995 Nov;13(4):901-14 [8584003.001]
  • [Cites] Acta Cytol. 1988 Nov-Dec;32(6):840-7 [3264435.001]
  • [Cites] Arch Ophthalmol. 1979 Aug;97(8):1505-7 [380534.001]
  • [Cites] Retina. 1984 Summer-Fall;4(3):135-43 [6387833.001]
  • [Cites] Surv Ophthalmol. 2000 May-Jun;44(6):518-26 [10906383.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1152-6 [9298056.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2003 Oct;241(10):860-70 [14605902.001]
  • [Cites] Ophthalmologe. 2003 Feb;100(2):145-9 [12589460.001]
  • (PMID = 14986704.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 50
  •  go-up   go-down


15. Schocket LS, Syed NA, Fine SL: Primary adrenal lymphoma with choroidal metastases. Am J Ophthalmol; 2002 Nov;134(5):775-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adrenal lymphoma with choroidal metastases.
  • PURPOSE: To describe a 71-year-old man with bilateral primary adrenal lymphoma with metastases to the choroid.
  • METHODS: A 71-year-old man presented with decreased visual acuity in his left eye secondary to an exudative retinal detachment.
  • Abdominal computed tomography and percutaneous biopsy revealed non-Hodgkin large-cell lymphoma involving both adrenal glands.
  • RESULTS: Ocular and adrenal lesions resolved after six cycles of chemotherapy with cytoxan, adriamycin, vincristine, and prednisone.
  • Seven years after his initial diagnosis, the patient reported no recurrence of either ocular or systemic lymphoma.
  • CONCLUSIONS: To our knowledge, this is the first case report of bilateral primary adrenal lymphoma with apparent metastases exclusively to the eye.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Choroid Neoplasms / secondary. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lymphatic Metastasis. Male. Retinal Detachment / etiology. Tomography, X-Ray Computed. Vision Disorders / etiology. Visual Acuity

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12429262.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Payne JF, Shields CL, Eagle RC Jr, Shields JA: Orbital lymphoma simulating thyroid orbitopathy. Ophthal Plast Reconstr Surg; 2006 Jul-Aug;22(4):302-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital lymphoma simulating thyroid orbitopathy.
  • An 82-year-old man with hypothyroidism had vertical diplopia and swelling around his left eye.
  • There was moderate blepharoptosis and edema of the left eyelids and superior scleral show of the right eye.
  • The left eye showed 4 mm of proptosis, motility restriction, afferent pupillary defect, and normal optic disc.
  • Muscle biopsy revealed large B-cell lymphoma.
  • The patient was treated with chemotherapy, immunotherapy, and radiotherapy, with complete tumor control.
  • Orbital lymphoma can simulate thyroid orbitopathy, even in patients with classic "thyroid-like" symptoms and imaging.
  • [MeSH-major] Graves Ophthalmopathy / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Oculomotor Muscles / pathology

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855508.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. El Kettani A, Lamari H, Lahbil D, Rais L, Zaghloul K: [Bilateral optic neuropathy and non-Hodkin's lymphoma]. Bull Soc Belge Ophtalmol; 2006;(300):35-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral optic neuropathy and non-Hodkin's lymphoma].
  • While ocular lesion is commonly known in lymphoma, optic neuropathy is very rare : 1,3% of lymphomas affecting the central nervous systems.
  • OBSERVATION: Authors report the case of a 75 year old patient treated in the haematology department for 8 years, for a large cell B phenotype stage IV lymphoma for which he received 7 chemotherapy courses (CHOP protocol).
  • The ophthalmologic exam revealed no light perception and no afferent reflex on the right eye.
  • There was light perception and weak afferent reflex on the left eye.
  • A chemotherapy with highly dosed IV and intrathecal methotrexate was performed.
  • DISCUSSION: the optic neuropathy is usually associated with a generalized lymphoma with central nervous system involvement, but sometimes can precede the systemic spread of the disease.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Optic Nerve Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Humans. Injections, Spinal. Male. Methotrexate / therapeutic use

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16903510.001).
  • [ISSN] 0081-0746
  • [Journal-full-title] Bulletin de la Société belge d'ophtalmologie
  • [ISO-abbreviation] Bull Soc Belge Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Maximiano Alonso C, Sánchez Ruiz AC, Cantos Sánchez de Ibargüen B, Méndez García M, Ronco IS, Provencio Pulla M: Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. Clin Transl Oncol; 2010 Oct;12(10):701-3
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab.
  • Primary brain lymphoma is a rare variant of extranodal non-Hodgkin's B-cell lymphoma.
  • In >90% of cases, this is diffuse large B-cell lymphoma with CD20 expression and is confined to the brain, meninges, spinal cord, and eyes.
  • The rate of relapse after initial therapy based on high-dose methotrexate and/or total brain irradiation is high.
  • There is no consensus for treating relapse, which ranges from retreatment with high doses of methotrexate, polychemotherapy, high doses of chemotherapy backed up by autologous stem-cell transplant to intrathecal chemotherapy, with widely differing results.
  • Given the lack of consensus and poor results, new therapy options have appeared, including immunotherapy with rituximab.
  • At a systemic level, alongside chemotherapy, its results are very modest and limited due to the low concentration it reaches in cerebrospinal fluid (CSF).
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Eye Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Focus. 2006 Nov 15;21(5):E11 [17134113.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):528-34 [16939963.001]
  • [Cites] Cancer. 2008 Sep 1;113(5):1025-31 [18618509.001]
  • [Cites] Blood. 2009 Jan 1;113(1):7-10 [18802010.001]
  • [Cites] Haematologica. 2004 Jun;89(6):753-4 [15194546.001]
  • [Cites] Oncologist. 2009 May;14(5):526-39 [19433528.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1350-6 [17312328.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2512-8 [18413641.001]
  • [Cites] J Neurooncol. 2008 Jan;86(2):211-5 [17896078.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):197-9 [16937012.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):794-5 [19036096.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):601-6 [15627024.001]
  • [Cites] Leuk Lymphoma. 2009 Jul;50(7):1110-8 [19557631.001]
  • [Cites] Retina. 2009 Feb;29(2):129-32 [19202422.001]
  • [Cites] Neurotherapeutics. 2009 Jul;6(3):587-97 [19560747.001]
  • [Cites] Lancet Neurol. 2009 Jun;8(6):581-92 [19446277.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):393-6 [19593137.001]
  • (PMID = 20947485.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


19. Beden U, Sonmez B, Kandemir B, Erkan D: Bilateral simultaneous primary orbital lymphoma presenting with unilateral enophthalmos. Ophthal Plast Reconstr Surg; 2008 Mar-Apr;24(2):145-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral simultaneous primary orbital lymphoma presenting with unilateral enophthalmos.
  • Hertel exophthalmometry readings were 6.0 mm in the right eye and 11.0 mm in the left eye with a base of 102 mm.
  • MRI revealed bilateral hypointense orbital soft-tissue masses.
  • Pathologic evaluation of incisional biopsy specimens revealed malignant tissue composed of diffuse, mitotically active, atypical large lymphoid cells positive for CD-20 with immunohistochemical staining, confirming the diagnosis of malignant diffuse large B-cell lymphoma.
  • After R-CHOP chemotherapy (Rituximab 375 mg/m2 intravenously, Cyclophosphamide 750 mg/m2 intravenously, Doxorubicin 50 mg/m2 intravenously, Vincristine 1.4 mg/m2 intravenously, Prednisolone 100 mg orally), Hertel measurements were 9.0 mm in the right eye and 11.0 mm in the left eye.
  • Although rare, non-Hodgkin lymphoma may present bilaterally as primary orbital lesions and can unexpectedly cause enophthalmos instead of proptosis.
  • [MeSH-major] Enophthalmos / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Entropion / etiology. Female. Functional Laterality. Humans. Magnetic Resonance Imaging. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356723.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. Iwase T, Sugiyama K, Takahira M, Uchiyama A: Intraocular lymphoma metastasis from larynx. Eur J Ophthalmol; 2007 Jan-Feb;17(1):133-5
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraocular lymphoma metastasis from larynx.
  • PURPOSE: To present a rare case of primary larynx diffuse large B cell lymphoma non-Hodgkin's lymphoma (NHL), disseminated to the cerebellum and the intraocular tissue.
  • RESULTS: The authors discovered diffuse large B cell NHL with cytopathologic examination from vitreous specimen in this case, which was identical with diffuse large B cell NHL of the larynx and cerebellum, and therefore could diagnose the intraocular lesion as the metastasis of NHL.
  • The authors treated by the combined curative chemotherapy and radiotherapy to ocular tissue, since providing sufficient evidence that the chorioretinal lesion was to predict the metastasis of diffuse large B cell NHL After those treatments, chorioretinal lesions have disappeared in both eyes and the vision has recovered.
  • CONCLUSIONS: Increased attention to the possibility of dissemination of laryngeal NHL to the intraocular tissue is needed.
  • [MeSH-major] Cerebellar Neoplasms / secondary. Eye Neoplasms / secondary. Laryngeal Neoplasms / pathology. Lymphoma, B-Cell / pathology. Vitreous Body / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Vitrectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294396.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Raparia K, Chang CC, Chévez-Barrios P: Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens. Arch Pathol Lab Med; 2009 Aug;133(8):1233-7
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens.
  • CONTEXT: Diagnosis and classification of primary intraocular lymphoma can be challenging because of the sparse cellularity of the vitreous specimens.
  • OBJECTIVE: To classify and clinically correlate intraocular lymphoma according to the World Health Organization (WHO) classification by using vitrectomy specimens.
  • DESIGN: Clinical history, cytologic preparations, flow cytometry reports, and outcome of 16 patients diagnosed with intraocular lymphoma were reviewed.
  • The cases included 9 primary diffuse large B-cell lymphomas of the CNS type; 2 diffuse large B-cell lymphomas, not otherwise specified; 1 extranodal, low-grade, marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT); 1 precursor B-lymphoblastic lymphoma; and 3 peripheral T-cell lymphomas, not otherwise specified.
  • Of note, all 11 cases of diffuse large B-cell lymphoma were CD10-.
  • All the patients received systemic chemotherapy and radiation therapy.
  • CONCLUSIONS: Intraocular lymphoma cases can be adequately classified according to the WHO classification.
  • Diffuse large B-cell lymphoma, CD10- and most likely of non-germinal center B-cell-like subgroup, is the most common subtype of non-Hodgkin lymphoma in this site, in contrast to ocular adnexal lymphoma for which MALT lymphoma is the most common subtype.
  • [MeSH-major] Eye Neoplasms / diagnosis. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis. Vitrectomy / methods. Vitreous Body / pathology
  • [MeSH-minor] Adult. Aged. Cytodiagnosis / methods. Female. Flow Cytometry. Humans. Lymphoma, B-Cell, Marginal Zone / classification. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Retrospective Studies. Survival Rate. Texas / epidemiology. World Health Organization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653716.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Heath JA, Broxson EH Jr, Dole MG, Filippa DA, George D, Lyden D, Dunkel IJ: Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue. J Pediatr Hematol Oncol; 2002 Feb;24(2):160-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.
  • In this article, a patient with EBV-lymphoma after autologous stem cell rescue for treatment of a nonhematologic solid tumor is described.
  • He had previously received both local tumor bed and craniospinal radiation therapy together with intensive myeloablative alkylator chemotherapy before autologous stem cell rescue.
  • Histologically confirmed lymphoma with evidence of active EBV proliferation developed within cervical lymph nodes 3 weeks after his first autologous stem cell rescue.
  • The patient died approximately 6 months later of persistent and progressive retinoblastoma without any clinical evidence of lymphoma.
  • It is concluded that EBV-LPD should be included in the differential diagnosis in patients in whom lymphadenopathy develops after autologous stem cell rescue.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Eye Neoplasms / pathology. Hematopoietic Stem Cell Transplantation. Herpesvirus 4, Human / isolation & purification. Lymphoma, Large B-Cell, Diffuse / etiology. Neoplasms, Second Primary / etiology. Retinoblastoma / secondary
  • [MeSH-minor] Acyclovir / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiviral Agents / therapeutic use. Carboplatin / administration & dosage. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Central Nervous System Neoplasms / secondary. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease Progression. Etoposide / administration & dosage. Eye Enucleation. Fatal Outcome. Humans. Immunocompromised Host. Immunoglobulins, Intravenous / therapeutic use. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Immunotherapy. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / secondary. Meningeal Neoplasms / therapy. Methylprednisolone / therapeutic use. Neoplasm Recurrence, Local. Optic Nerve Neoplasms / radiotherapy. Optic Nerve Neoplasms / secondary. Radiotherapy, Adjuvant. Rituximab. Thiotepa / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11998794.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents, Phytogenic; 0 / Antiviral Agents; 0 / Immunoglobulins, Intravenous; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin; X4HES1O11F / Acyclovir; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


23. Claeys A, Trullemans F, Maes J, Hennekes R, Salu P: Diplopia as an initial manifestation of disseminated non-hodgkin's lymphoma. Bull Soc Belge Ophtalmol; 2002;(286):35-8
MedlinePlus Health Information. consumer health - Optic Nerve Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diplopia as an initial manifestation of disseminated non-hodgkin's lymphoma.
  • Ocular examination showed a partial paresis of the left eye (LE) on the left gaze, progressing in a few days towards a total ophthalmoplegia.
  • Further investigation revealed an intra-orbital mass, immunohistologically diagnosed as a Diffuse Large B-cell Lymphoma (DLBCL), according to the WHO classification.
  • Since the patient was in an advanced, disseminated stage of the disease (IVA-E), treatment was based on systemic and intrathecal chemotherapy with a pancranial radiotherapy.
  • We wish to stress that the possibility of orbital malignancy in young adults with acute onset of ophthalmoplegia should be included in the differential diagnosis.
  • [MeSH-major] Diplopia / etiology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / diagnosis. Optic Nerve Diseases / radiography. Orbital Neoplasms / radiography
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bronchi / pathology. Bronchoscopy. Fatal Outcome. Humans. Lung / radiography. Male. Pancreatic Neoplasms / pathology. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12564315.001).
  • [ISSN] 0081-0746
  • [Journal-full-title] Bulletin de la Société belge d'ophtalmologie
  • [ISO-abbreviation] Bull Soc Belge Ophtalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


24. Gorsane I, Bourkhis L, Laatiri MA, Aloui S, Letaif A, Haouala F, Ben Dhia N, Frih A, Zakhama A, Elmay M, Skhiri H: [Acute renal failure caused by renal lymphoma. A case report]. Nephrol Ther; 2010 Apr;6(2):132-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute renal failure caused by renal lymphoma. A case report].
  • Acute renal failure, as the initial manifestation of lymphoma, has been reported only in a few cases.
  • A 24-hour urine collection analysis allowed the detection of 1g of protein.
  • Renal biopsy of the kidney and pathologic examination showed diffuse infiltration of the interstitium with lymphocytes and atypical cells positive for CD20 markers.
  • A diagnosis of diffuse large B-cell type non-Hodgkin lymphoma was made.
  • However, investigations revealed the presence of two others sites of lymphoma: gastric and ophthalmic.
  • The patient's renal function and kidney size as well as the other lymphoma locations were normalized after the initiation of chemotherapy.
  • [MeSH-major] Acute Kidney Injury / etiology. Eye Neoplasms / diagnosis. Kidney Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Neoplasms, Multiple Primary / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD20 / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Diagnosis, Differential. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20299297.001).
  • [ISSN] 1872-9177
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Watanabe K, Arai A, Takase H, Takahashi H, Iwanaga Y, Sugamoto Y, Sugita S, Mochizuki M, Miura O: [Primary intraocular lymphoma invaded to the central nervous system after successful treatment with intraocular methotrexate injection]. Rinsho Ketsueki; 2009 Mar;50(3):182-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intraocular lymphoma invaded to the central nervous system after successful treatment with intraocular methotrexate injection].
  • He had opacity in the vitreous body and white lesions in the retina of the right eye.
  • Although cytological examinations of the vitreous samples revealed Class II, the diagnosis of primary intraocular lymphoma (PIOL) was made by detecting both IgH rearrangement by PCR and an elevated ratio of IL-10/IL-6 concentration in the vitreous sample.
  • Two months later (10 months after appearance of the right eye lesion), however, the same lesions appeared in the left eye.
  • Cytological examinations of the left vitreous sample revealed Class V by detecting large abnormal lymphocytes.
  • Although intravitreal MTX injections were also effective, central nervous system (CNS) involvement appeared only 2 months after the left eye lesions appeared.
  • Open biopsy was performed and a diagnosis of diffuse large B-cell lymphoma was made.
  • Diagnosis of PIOL is difficult.
  • Since local treatment was considered insufficient, an optimal treatment strategy for PIOL should be established.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Eye Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Methotrexate / administration & dosage. Vitreous Body

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352085.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Vascellari M, Multari D, Mutinelli F: Unicentric extranodal lymphoma of the upper eyelid conjunctiva in a dog. Vet Ophthalmol; 2005 Jan-Feb;8(1):67-70
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unicentric extranodal lymphoma of the upper eyelid conjunctiva in a dog.
  • A case of conjunctival lymphoma in a 4-year-old Siberian husky is reported.
  • A large red mass protruding from the conjunctiva of the upper eyelid of the right eye was present.
  • After anti-inflammatory treatment, surgery was performed.
  • Histologically, the mass consisted of large polygonal cells with a high nucleus to cytoplasm ratio, moderate amounts of slightly eosinophilic cytoplasm, pleomorphic nuclei with vesicular chromatin and prominent multiple nucleoli.
  • On the basis of histologic and immunohistochemical findings, a diagnosis of intermediate-grade, diffuse large-cell lymphoma with T-cell immunophenotype was made.
  • The surgical area healed uneventfully and, although chemotherapy was not received, after 12 months the dog exhibited no recurrence.
  • To the authors' knowledge, this is the first report of unicentric extranodal conjunctival lymphoma in a dog.
  • [MeSH-major] Dog Diseases / diagnosis. Eyelid Neoplasms / veterinary. Lymphoma / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Dogs. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644103.001).
  • [ISSN] 1463-5216
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Raoux D, Duband S, Forest F, Trombert B, Chambonnière ML, Dumollard JM, Khaddage A, Gentil-Perret A, Péoc'h M: Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance. Neuropathology; 2010 Jun;30(3):232-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance.
  • Primary central nervous system lymphoma (PCNSL) is a rare subtype of non-Hodgkin lymphoma (NHL) with extranodal location affecting only the CNS, meninges and eye, without visceral or lymph node involvement.
  • Most PCNSL cases are diffuse large B-cell lymphomas (DLBCLs).
  • Two prognostic algorithms were then prepared using a panel of immunohistochemical markers (CD10, Bcl6, MUM1/IRF-4, and Bcl2), thus categorizing DLBCL into two subgroups, GCB (germinal centre B-cell-like) or non-GCB, and into Group 1 or Group 2.
  • Younger age (<65) and a therapeutic combination of chemotherapy and radiotherapy significantly improved our patients' survival rates.
  • [MeSH-major] Central Nervous System Neoplasms / chemistry. Central Nervous System Neoplasms / immunology. Lymphoma, B-Cell / chemistry. Lymphoma, B-Cell / immunology. Lymphoma, Non-Hodgkin / chemistry. Lymphoma, Non-Hodgkin / immunology

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925562.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Mineo JF, Scheffer A, Karkoutly C, Nouvel L, Kerdraon O, Trauet J, Bordron A, Dessaint JP, Labalette M, Berthou C, Labalette P: Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci; 2008 Nov;49(11):4738-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The treatment of primary central nervous system lymphoma (PCNSL) and its subset, primary intraocular lymphoma (PIOL), remains of limited efficiency, and salvage therapies are often used without prior testing in adequate animal models.
  • Most PNCSL/PIOL are aggressive B-cell malignancies.
  • METHODS: Human CD20-transfected murine B-lymphoma cells (38C13 CD20(+)) were inoculated in the vitreous through the pars plana or in the caudate nucleus with the use of a stereotaxic frame in immunocompetent syngeneic mice.
  • RESULTS: Inoculation of 38C13 CD20(+) cells in the eye or the brain resulted in tumor occurrence after a median of 15 days or 22 days, respectively, with histologic characteristics closely resembling those of PIOL and PCNSL.
  • Local rituximab injections eradicated tumor colonization in more than half the graft recipients and inhibited tumor progression significantly in the others compared with progression in mice that underwent grafting with the control 38C13 cell line (no human CD20 expression) and in mice that underwent grafting with 38C13 CD20(+) cells that received local injections of an irrelevant antibody (trastuzumab).
  • CONCLUSIONS: Inoculation of native or human CD20-transfected murine 38C13 cells in the vitreous or the brain of immunocompetent mice provides useful novel models for evaluating the biology and treatment of PIOL and PCNSL.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / immunology. Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Cell Line, Tumor. Cerebrum. Flow Cytometry. Immunohistochemistry. Injections. Mice. Mice, Inbred C3H. Neoplasms, Experimental. Rituximab. Treatment Outcome. Vitreous Body

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552383.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


29. Blay JY, Ongolo-Zogo P, Sebban C, Carrie C, Thiesse P, Biron P: Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer. Ann Oncol; 2000;11 Suppl 1:39-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer.
  • BACKGROUND: Primary cerebral non-Hodgkin's lymphomas (NHL) in immunocompetent patients (PCL) are located exclusively in the central nervous system, the eye, or meninges.
  • RESULTS: Most PCL are diffuse large-cell NHL with a B phenotype.
  • The overall survival of primary cerebral lymphoma (PCL) patients in the published series, a median of 12-16 months and a five-year survival of 5%-20%, is poor.
  • The optimal treatment of PCL is not known.
  • Complete resection of the tumor does not improve outcome and multidisciplinary approaches combining chemotherapy and radiotherapy are now commonly used, although the superiority of combination over radiotherapy- or chemotherapy-alone has never been demonstrated in a phase III trial.
  • The optimal chemotherapy regimen, the dose and even the usefulness of brain radiotherapy after chemotherapy are therefore still matters of debate.
  • Recently, several authors have reported a relatively high incidence of late neurological sequelae after PCL treatment.
  • CONCLUSIONS: The optimal treatment of PCL patients remains to be defined.
  • Large cooperative international phase III trials are now required to define and improve the optimal treatment of PCL and reduce its sequelae.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707777.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 28
  •  go-up   go-down


30. Farmer JP, Lamba M, Lamba WR, Jordan DR, Gilberg S, Sengar DP, Bence-Bruckler I, Burns BF: Lymphoproliferative lesions of the lacrimal gland: clinicopathological, immunohistochemical and molecular genetic analysis. Can J Ophthalmol; 2005 Apr;40(2):151-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesions were categorized according to the latest World Health Organization classification of tumours of lymphoid tissues.
  • The 5 primary lymphomas, of mucosa-associated lymphoid tissue (MALT), were confined to the lacrimal gland (stage IE); 1 tumour transformed to diffuse large B-cell lymphoma, necessitating chemotherapy, and the other 4 were treated with radiation.
  • The 6 secondary lymphomas (4 follicular) presented either concurrently with systemic lymphoma or up to 12 years afterwards and were treated in a variety of ways; all the patients had an orbital relapse.
  • At the last follow-up assessment, 6 of the patients with lymphoma had no evidence of disease, 3 were alive with disease, 2 had died (1 of lymphoma, the other with no evidence of disease), and the status of 1 patient was not known.
  • All 9 lymphomas that underwent molecular genetic analysis were of B-cell lineage, and 8 had a monoclonal rearrangement in the immunoglobulin heavy-chain gene (IgH); the 9th lymphoma showed an oligoclonal rearrangement.
  • One lymphoma showed the t(14;18) translocation, typical of follicular lymphoma; no lymphoma showed the t(11;18) translocation, commonly found in MALT lymphoma (but only 2 cases were studied).
  • INTERPRETATION: Lacrimal gland lymphomas are B-cell tumours that develop in older adults.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049528.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


31. Ohguro N, Hashida N, Tano Y: Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol; 2008 Jul;126(7):1002-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Eye Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18625954.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down






Advertisement